Ω-3 fatty acids have been tested for the treatment of cancer
anorexia/weight loss, a syndrome that predicts a poor prognosis among cancer
patients with incurable disease. This review focuses on both the preclinical
and clinical data of ω-3 fatty acids for treating this syndrome.
Overall, the promise of the former does not seem to be borne out completely in
the latter. This review includes a discussion of how these data might be
interpreted and explained to cancer patients who are striving to cope with
this syndrome.
Get full access to this article
View all access options for this article.
References
1.
Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss
prior to chemotherapy in cancer patients: Eastern Cooperative Oncology Group.
Am J Med.1980;69:491–
497.
2.
Cohn SH, Gartenhaus W, Sawitsky A, et al. Compartmental body
composition of cancer patients by measurement of total body nitrogen,
potassium, and water. Metabolism.1981
;30:222–
229.
3.
Moore FD. Energy and the maintenance of the body cell mass.
JPEN J Parenter Enteral Nutr.1980
;4:228–
260.
4.
Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body cell
mass depletion and the timing of death from wasting in AIDS. Am J
Clin Nutr.1989;50:444–
447.
5.
Holden CM. Anorexia in the terminally ill cancer patient: the
emotional impact on the patient and family. Hosp J.1991
;24:73–
84.
6.
Poole K, Froggatt K. Loss of weight and loss of appetite in
advanced cancer: a problem for the patient, the carer, or the health
professional? Palliat Med.2002
;16:499–
506.
7.
Jatoi A, Kumar S, Sloan JA, Nguyen PL. On appetite and its loss.
J Clin Oncol.2003
;21(suppl 9):79–
81.
8.
Rosenberg IH. Fish: food to calm the heart. N Engl J
Med.2002;346:1102–
1103.
9.
Baracos VE, DeVivo C, Hoyle DH, Goldberg AL. Activation of the
ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing
a hepatoma. Am J Physiol.1995
;268(5 pt 1):E996–
E1006.
10.
Lazarus DD, Destree AT, Mazzola LM, et al. A new model of cancer
cachexia: contribution of the ubiquitin-proteasome pathway. Am J
Physiol.1999;277:E332–
E341.
11.
Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle
proteasome activity correlates with disease severity in gastric cancer
patients. Ann Surg.2003
;237:384–
389.
12.
Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ. Mechanism of
attenuation of skeletal muscle protein catabolism in cancer cachexia by
eicosapentaenoic acid. Cancer Res.2001
;61:3604–
3609.
13.
Wigmore SJ, Fearon KCH, Maingay JP, Garden OJ, Ross JA. Down
regulation of the acute phase response in patients with pancreatic cancer
cachexia receiving eicosapentaenoic acid is mediated via suppression of
interleukin-6. Clin Sci (Lond).1997;92
: 215–221.
14.
Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M.
Characterization of a cancer cachectic factor. Nature.1996
;379:739–
742.
15.
Smith HJ, Lorite MJ, Tisdale MJ. Effect of a cancer cachectic
factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation
by eicosapentaenoic acid. Cancer Res.1999
;59:5507–
5513.
16.
Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC,
Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E
restore immunodeficiency and prolong survival for severely ill patients with
generalized malignancy: a randomized controlled trial.
Cancer.1998;82:395–
402.
17.
Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of
an oral nutrition supplement enriched with fish oil on weight-loss in patients
with pancreatic cancer. Br J Cancer.1999
;81:80–
86.
18.
Fearon KC, von Meyenfeldt MF, Moses AG, et al. Effect of a protein
and energy dense n-3 fatty acid enriched oral supplement on loss of weight and
lean tissue in cancer cachexia: a randomised double blind trial.2003
; Gut.52:1479–
1486.
19.
Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on
appetite and other symptoms in patients with advanced cancer and
anorexia/cachexia: a double-blind, placebo-controlled study. J Clin
Oncol.2003;21:129–
134.
20.
Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid
supplement versus megestrol acetate versus both for patients with
cancer-associated wasting: a North Central Cancer Treatment Group and National
Cancer Institute of Canada collaborative effort. J Clin
Oncol.2004;22:2469–
2476.
21.
Burch PA, Block M, Schroeder G, et al. Phase III evaluation of
octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus
leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer
Treatment Group study. Clin Cancer Res.2000
;6:3486–
3492.
22.
Sarhill N, Mahmoud F, Walsh D, et al. Evaluation of nutritional
status in advanced metastatic cancer. Support Care
Cancer.2003;11:652–
659.
